FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308134193> ?p ?o ?g. }

• W4308134193 endingPage "A570" @default.
• W4308134193 startingPage "A570" @default.
• W4308134193 abstract "Abstract Background Pituitary apoplexy (PA) is characterized by sudden increase in pituitary gland volume secondary to ischemia and/or necrosis. Certain predisposing factors can result in PA and use of gonadotropin-releasing hormone (GnRH) agonist for prostate cancer (PCa) is one such condition. We present a case of 59-year-old male who had insidious onset of PA following leuprolide administration, resulting in late presentation of PA. Case Presentation A 59-years old male was referred to the endocrinology clinic for evaluation of pituitary enlargement found on MRI brain in June 2021. He complained of fatigue, anorexia, unintentional weight loss, diplopia, and blurry vision, which developed insidiously and gradually worsened over six months. In 2014, he was diagnosed with stage 4 PCa (Gleason Score=8) with metastasis to the lymph nodes, ribs, and pelvic bones and underwent palliative radiation for bone metastasis and androgen deprivation with intramuscular leuprolide 22.5 mg every 3 months between July 2014 till July 2020. On presentation, he was hemodynamically stable and visual field testing was negative. Anterior pituitary hormone evaluation revealed panhypopituitarism with low serum ACTH 5 pg/ml (7.2-63.3 pg/ml), cortisol 2.9 mcg/dl (5-15 mcg/dl), TSH 0.53 mclIU/ml (0.6-4.7 mclIU/ml), Free T4 0.27 ng/dl (0.58-1.76 ng/dl), IGF-1 58 ng/ml (54-258 ng/ml), LH 0.3 mIU/ml (1.5-9.3 mIU/ml), FSH 1 mIU/ml (1.4-18 mIU/ml) and testosterone &lt; 3 ng/dl (1.5-9.3 ng/dl). Pituitary MRI July 2021 demonstrated subacute hemorrhage inside the pituitary gland which was not present in prior MRI in September 2020. Based on laboratory work up showing secondary adrenal insufficiency and central hypothyroidism, as well as pituitary imaging confirming apoplectic event, he was diagnosed with PA secondary to GnRH agonist use. He was initially treated with stress dose of steroids followed by prednisone 5 mg daily and levothyroxine 75 mcg daily. He had significant improvement of symptoms over next few weeks including near complete resolution of visual symptoms. Conclusion Given high prevalence of PCa and increased use of GnRH agonists, more patients will develop PA, which was once thought to be extremely rare. Furthermore, it is critical that patients receiving GnRH agonists should be evaluated for possible PA, even in the absence of acute symptoms, which is classically seen in PA. Presentation: Monday, June 13, 2022 12:30 p.m. - 2:30 p.m." @default.
• W4308134193 created "2022-11-08" @default.
• W4308134193 creator A5053190469 @default.
• W4308134193 creator A5080831903 @default.
• W4308134193 creator A5088209267 @default.
• W4308134193 date "2022-11-01" @default.
• W4308134193 modified "2023-09-29" @default.
• W4308134193 title "PMON91 Late Presentation of Pituitary Apoplexy Following Gonadotropin-Releasing Hormone Agonist for Prostate Cancer Treatment" @default.
• W4308134193 doi "https://doi.org/10.1210/jendso/bvac150.1183" @default.
• W4308134193 hasPublicationYear "2022" @default.
• W4308134193 type Work @default.
• W4308134193 citedByCount "0" @default.
• W4308134193 crossrefType "journal-article" @default.
• W4308134193 hasAuthorship W4308134193A5053190469 @default.
• W4308134193 hasAuthorship W4308134193A5080831903 @default.
• W4308134193 hasAuthorship W4308134193A5088209267 @default.
• W4308134193 hasBestOaLocation W43081341931 @default.
• W4308134193 hasConcept C121608353 @default.
• W4308134193 hasConcept C126322002 @default.
• W4308134193 hasConcept C126894567 @default.
• W4308134193 hasConcept C134018914 @default.
• W4308134193 hasConcept C2777428134 @default.
• W4308134193 hasConcept C2777637523 @default.
• W4308134193 hasConcept C2778491484 @default.
• W4308134193 hasConcept C2779279991 @default.
• W4308134193 hasConcept C2779318953 @default.
• W4308134193 hasConcept C2780192828 @default.
• W4308134193 hasConcept C71924100 @default.
• W4308134193 hasConceptScore W4308134193C121608353 @default.
• W4308134193 hasConceptScore W4308134193C126322002 @default.
• W4308134193 hasConceptScore W4308134193C126894567 @default.
• W4308134193 hasConceptScore W4308134193C134018914 @default.
• W4308134193 hasConceptScore W4308134193C2777428134 @default.
• W4308134193 hasConceptScore W4308134193C2777637523 @default.
• W4308134193 hasConceptScore W4308134193C2778491484 @default.
• W4308134193 hasConceptScore W4308134193C2779279991 @default.
• W4308134193 hasConceptScore W4308134193C2779318953 @default.
• W4308134193 hasConceptScore W4308134193C2780192828 @default.
• W4308134193 hasConceptScore W4308134193C71924100 @default.
• W4308134193 hasIssue "Supplement_1" @default.
• W4308134193 hasLocation W43081341931 @default.
• W4308134193 hasLocation W43081341932 @default.
• W4308134193 hasOpenAccess W4308134193 @default.
• W4308134193 hasPrimaryLocation W43081341931 @default.
• W4308134193 hasRelatedWork W1983047987 @default.
• W4308134193 hasRelatedWork W1998113603 @default.
• W4308134193 hasRelatedWork W1999611386 @default.
• W4308134193 hasRelatedWork W1999831221 @default.
• W4308134193 hasRelatedWork W2005007743 @default.
• W4308134193 hasRelatedWork W2027237635 @default.
• W4308134193 hasRelatedWork W2036308844 @default.
• W4308134193 hasRelatedWork W2047880909 @default.
• W4308134193 hasRelatedWork W2087168955 @default.
• W4308134193 hasRelatedWork W2100202028 @default.
• W4308134193 hasVolume "6" @default.
• W4308134193 isParatext "false" @default.
• W4308134193 isRetracted "false" @default.
• W4308134193 workType "article" @default.